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ABSTRACT 24 
 25 
Six new peptides were isolated from the venom of the Mexican scorpion Centruroides 26 
tecomanus; their primary structures were determined and the effects on ion channels were 27 
verified by patch-clamp experiments. Four are K+-channel blockers of the α-KTx family, 28 
containing 32 to 39 amino acid residues, cross-linked by three disulfide bonds. They all 29 
block Kv1.2 in nanomolar concentrations and show various degree of selectivity over 30 
Kv1.1, Kv1.3, Shaker and KCa3.1 channels. One peptide has 42 amino acids cross-linked 31 
by four disulfides; it blocks ERG-channels and belongs to the γ-KTx family. The sixth 32 
peptide has only 32 amino acid residues, three disulfide bonds and has no effect on the ion-33 
channels assayed.  It also does not have antimicrobial activity. Systematic numbers were 34 
assigned (time of elution on HPLC): α-KTx 10.4 (time 24.1); α-KTx 2.15 (time 26.2); α-35 
KTx 2.16 (time 23.8); α-KTx 2.17 (time 26.7) and γ-KTx 1.9 (elution time 29.6). A partial 36 
proteomic analysis of the short chain basic peptides of this venom, which elutes on 37 
carboxy-methyl-cellulose column fractionation, is included. The pharmacological 38 
properties of the peptides described in this study may provide valuable tools for 39 
understanding the structure-function relationship of K+ channel blocking scorpion toxins.    40 
 41 
 42 
1. INTRODUCTION 43 
 44 
Scorpion venom components display important pharmacological activities, which have 45 
been used in the past for physiological characterization of ion channels, possible 46 
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development of new antibiotics, anti-malaria agents, specific enzymatic functions and 47 
development of anti-venoms, among other activities (Ortiz et al., 2015; Possani et al., 48 
1999). Recently, several publications dealing with proteomic and transcriptomic analysis of 49 
scorpion venoms have been published, starting with (Schwartz et al., 2007) followed by 50 
(Abdel-Rahman et al., 2013; Diego-Garcia et al., 2012; He et al., 2013; Luna-Ramirez et 51 
al., 2015; Luna-Ramirez et al., 2013; Ma et al., 2012; Ma et al., 2010; Rendon-Anaya et al., 52 
2012; Smith et al., 2012), and others, revised in (Rendón-Anaya et al., 2014).  Among the 53 
main constituents of these venoms are proteins (enzymes such as hyaluronidase, 54 
phospholipases, proteases with hydrolytic effects), peptides that block or modulate ion 55 
channels  (Na+, K+, Ca2+,  or Cl- channels), free amino acids, biogenic amines, nucleotides, 56 
carbohydrates, lipids and many small molecular weight components of unknown function 57 
(see reviews (Ortiz et al., 2014; Possani et al., 1999; Rodriguez de la Vega and Possani, 58 
2005; Smith and Alewood, 2014)). From the huge diversity of scorpions known (over 2,000 59 
different species, as compiled by (Dunlop and Penney, 2012)), in the world, only a minor 60 
fraction have been studied in some extent concerning the molecular biology of their 61 
components and their corresponding activities. A few recent reviews in the literature can be 62 
consulted on the subject (Bartok et al., 2015; Gurevitz et al., 2014; Martin-Eauclaire et al., 63 
2014; Santibanez-Lopez and Possani, 2015). México among the richest regions in the world 64 
on scorpion diversity, only those belonging to the Centruroides and a few other genera, 65 
such as Hadrurus, Anuroctonus and Vaejovis have been studied thus far. All the dangerous 66 
species to humans in the country belong to the genus Centruroides. One of the most lethal 67 
venoms is from the scorpion of the state of Colima, Centruroides tecomanus. From this 68 
scorpion several peptides that impair proper function of Na+-channels of excitable cells 69 
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were previously isolated and characterized (Martin et al., 1988; Possani et al., 1980; 70 
Ramirez et al., 1988), and more recently a proteomic and transcriptomic analysis was 71 
published (Valdez-Velazquez et al., 2013). According to the transcriptomic analysis the 72 
venom of C. tecomanus contains peptides whose amino acid sequence was similar to other 73 
known scorpion toxins that block K+-channels (KTx), but none of these putative peptides 74 
have been formerly studied at the chemical and functional level. Here we describe the 75 
isolation of six new peptides, whose complete primary structure was determined and the 76 
specific effects on voltage-dependent K+-channels were identified. Many peptides from 77 
scorpion venom that inhibit potassium channels are known, which permitted the 78 
establishment of a systematic nomenclature. Based on structural characteristics these 79 
peptides are classified as: α, β, γ and κ KTx families (Rodriguez de la Vega and Possani, 80 
2004; Tytgat et al., 1999). The largest group is the α-KTx. These toxins are typically 23-43 81 
amino acid long oligopeptides with three or four disulfide bonds stabilizing their 3D 82 
structure.  Many of them show high specificity and uniquely high affinity to a targeted 83 
channel. They generally possess a conserved amino acid pair called the essential dyad, 84 
which consists of a lysine and another, usually aromatic residue in a distance of circa 7 85 
Angstroms. (Dauplais et al., 1997). As the positively charged lysine intrudes the selectivity 86 
filter of K+ channels this dyad plays important role in the channel blocking ability. The 87 
primary structure of the peptides, the arrangement of the dyad and its surrounding residues 88 
will define the selectivity and affinity for the various types of K+-channels. In this paper we 89 
describe four new α-KTxs, one γ-KTx and an orphan peptide for which the function is thus 90 
far unknown. 91 
 92 
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 93 
 94 
2. MATERIAL AND METHODS 95 
 96 
2.1 Venom source, chemical and reagents 97 
Scorpions collected in Colima State (Mexico) with official permission from SEMARNAT 98 
(number MOR-IN-166-07-04) were milked for venom by electrical stimulation. The venom 99 
was dissolved in water, centrifuged at 10,000 g for 20 minutes and the supernatant was 100 
lyophilized and kept at -20 ºC until use. All chemicals and reagents were analytical grade 101 
substances. Double distilled water was used through all the procedures.  102 
 103 
2.2 Purification of peptides 104 
The purification strategy initially described by our group was followed for the isolation of 105 
the peptides, with small modifications. The soluble venom was separated by gel filtration 106 
on Sephadex G-50 column, in 20 mM ammonium acetate buffer, pH 4.7, exactly as earlier 107 
described (Ramirez et al., 1988). The toxic fraction II from Sephadex column was applied 108 
to ion-exchange purification on carboxy-methyl-cellulose (CM-cellulose) resins. The 109 
column was equilibrated with the same buffer, but eluted with a salt gradient from 0 to 0.5 110 
M sodium chloride (the earlier gradient was from 0 to 0.4 M NaCl). The CM-cellulose 111 
fractions of interest were further separate by high performance liquid chromatography 112 
(HPLC), using an analytical C18 reverse-phase column (4.6 x 250 mm from Vydac, 113 
Hysperia, CA. USA), not used in the earlier procedure. The pure peptides were obtained by 114 
means of a linear gradient from solution A (0.12% trifluoroacetic acid (TFA) in water to 115 
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60% solution B (0.10% TFA in acetonitrile), run for 60 min. The detection was monitored 116 
by absorbance at λ = 230 nm and components were manually collected, freeze-dried using a 117 
Savant SpeedVac dryer and used for chemical and functional characterization as described 118 
below.   119 
 120 
2.3 Sequence by Edman degradation and mass spectrometry analysis 121 
Purity of peptides was verified by three means: elution profile from HPLC (single peaks), 122 
mass spectrometry analysis (see below) and amino acid sequencing on a PPSQ-31A Protein 123 
Sequencer from Shimadzu Scientific Instruments, Inc. (Columbia, Maryland, USA). 124 
Usually a sample of native peptide (circa 0.5 nmoles) was directed loaded for sequence and 125 
a reduced and alkylated sample of the same peptide was additionally sequenced for 126 
identification of the cysteine residues. When necessary fractionation of clean peptides were 127 
obtained by protease digestion or cyanogen bromide cleavage as described below and the 128 
corresponding peptides were purified by HPLC and placed in the automatic Sequencer. 129 
Mass spectrometry analysis of peptides was performed using a LCQFleet apparatus from 130 
Thermo Fisher Scientific Inc. (San Jose, CA, USA).  131 
The protein sequence data reported in this paper will appear in the UniProt Knowledgebase 132 
under the accession numbers: C0HJW2 for α-KTx 10.4 (time 24.1); C0HJW1  for α-KTx 133 
2.15 (time 26.2); C0HJW6 for  α-KTx 2.16 (time 23.8); C0HJW5 for α-KTx 2.17 (time 134 
26.7) and C0HJW3 for  γ-KTx 1.9 (elution time 29.6). 135 
 136 
2.4 Alkylation, digestion and chemical cleavage 137 
 138 
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For reduction, the pure peptides were dissolved in 200 mM TRIS-HCl buffer, pH 8.6 139 
containing 1 mg/mL EDTA and 6 M guanidinium chloride, to which 2 mg of dithiotreitol 140 
(DDT) was added. Nitrogen was bubbled to the solution for 5 min and stored 45 min at 55 141 
ºC. Immediately after 2.5 mg of Iodoacetamide was added to the reacting vial, placed in the 142 
dark and let stand for 30 min. Finally, the reduced and alkylated peptide was applied to a 143 
C18 reverse-phase column for elimination of reagents (similar conditions than described 144 
above). When the sequencing procedure showed that the full sequence was not completed, 145 
the peptides were either treated with cyanogens bromide or cleaved with protease V8 from 146 
Staphylococcus aureus. For enzymatic digestion the reduced and alkylated sample (usually 147 
50 µg) was dissolved in 100 mM ammonium bicarbonate buffer, pH 7.8 and added 2 µg of 148 
protease v8 (Mannheim, Germany) and incubated at 37 ºC over-night. The digested sample 149 
was separated by HPLC using the same conditions used for purification of peptides and the 150 
products identified on the Sequencer. Alternatively, the reduced and alkylated pure peptides 151 
were chemically cleaved with cyanogen bromide. Normally, to 50 µg of peptide dissolved 152 
in 100 µL of 70% formic acid it was added 5 mg of cyanogen bromide (Sigma-Aldrich, St. 153 
Louis, MO, USA) until completely dissolved, sealed and covered from light and let stand 154 
for 4 h at room temperature. Immediately after, 50 µL of octanol were added and the 155 
solution was evaporated with a nitrogen stream. The products were also separated by HPLC 156 
and sequenced as described above.  157 
 158 
2.5 Amino acid comparison of peptide sequences 159 
 160 
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C. tecomanus peptide sequences were compared with known sequences using NCBI 161 
BLAST.  162 
 163 
2.6 Cell culture and manipulation  164 
 165 
Antimicrobial activity was assayed according to Ramirez-Carreto et al., (2015). 166 
For electrophysiological experiments (see below)  tsA201 cells (Shen et al., 1995) were 167 
cultured under standard conditions, as described previously (Corzo et al., 2008). Human 168 
peripheral lymphocytes were drawn from healthy volunteers. Mononuclear cells were 169 
isolated using Ficoll-Hypaque density gradient separation technique and were grown in 24-170 
well culture plates in a 5% CO2 incubator at 37°C in RPMI 1640 medium supplemented 171 
with 10% fetal calf serum (Sigma-Aldrich), 100 µg/ml penicillin, 100 µg/ml streptomycin, 172 
and 2 mM L-glutamine (density, 5 x 105 cells per ml) for 2 to 5 days. 5, 7.5 or 10 µg/ml 173 
phytohemagglutinin A (Sigma-Aldrich) was added to the medium to increase K+ channel 174 
expression.  175 
Kv1.1, Kv1.2, KCa3.1, Shaker-IR, Kv10.1 (EAG) and Kv11.1 (hERG) channel coding 176 
vectors were transfected in tsA201 cells using Ca2+ phosphate transfection kit (Sigma-177 
Aldrich, Hungary) according to the manufacturer’s instructions. hKv1.1 and hKv1.2 genes 178 
are coded in pCMV6-GFP plasmid (OriGene Technologies, Rockville, MD), hKCa3.1 in 179 
pEGFP-C1 vector (gift from H. Wulff, University of California, Davis CA).  180 
Shaker-IR (inactivation ball deletion mutant) (gift from G. Yellen, Harvard Medical 181 
School, Boston, MA), Kv10.1 (EAG, gift from L. Pardo, Max Planck Institute for 182 
Experimental Medicine, Göttingen, Germany) and hKv11.1 (hERG, kind gift from SH. 183 
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Heinemann, Max-Plank-Gesellschaft, Jena, Germany) coding plasmids were co-transfected 184 
with plasmid containing the gene of GFP in a molar ratio of 10:1 (Bartok et al., 2014).  185 
For the measurements of hKv1.3 currents activated lymphocytes were used (Bartok et al., 186 
2014).  187 
 188 
2.7 Electrophysiology  189 
 190 
Measurements were carried out using patch-clamp technique in voltage-clamp mode in 191 
whole-cell or outside-out patch configuration. For the recordings Axon Axopatch 200B or 192 
multiclamp 700B amplifiers and Axon Digidata 1440 digitizer were used (Molecular 193 
Devices, Sunnyvale, CA). Micropipettes were pulled from GC 150 F-15 borosilicate 194 
capillaries (Harvard Apparatus Kent, UK) resulting in 3- to 5-MΩ resistance in the bath 195 
solution. Generally the extracellular solution consisted of 145 mM NaCl, 5 mM KCl, 1 mM 196 
MgCl2, 2.5 mM CaCl2, 5.5 mM glucose, 10 mM HEPES, pH 7.35. For the measurements of 197 
hKv11.1 (hERG) channels the bath solution contained 5 mM KCl, 10 mM HEPES, 20 mM 198 
glucose, 2 mM CaCl2, 2 mM MgCl2, 0.1 mM CdCl2, 140 mM choline-chloride, pH 7.35. 199 
Bath solutions were supplemented with 0.1 mg/ml BSA when toxins were dissolved. The 200 
osmolarity of the extracellular solutions was between 302 and 308 mOsM/L. For the 201 
measurements of Kv1.1, Kv1.2, Kv1.3 and Shaker currents the pipette solution contained 202 
140 mM KF, 2 mM MgCl2, 1 mM CaCl2, 10 mM HEPES and 11 mM EGTA, pH 7.22. To 203 
measure on Kv11.1 channels the intracellular solution consisted of 140 mM KCl, 10 mM 204 
HEPES, 2mM MgCl2 and 10 mM EGTA, pH 7.22, for the KCa3.1 recordings it contained 205 
150 mM K-aspartate, 5mM HEPES, 10 mM EGTA, 8.7 mM CaCl2, 2 mM MgCl2, pH 7.22 206 
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resulting in 1 µM free Ca2+ in the solution to activate KCa3.1 channels (Grissmer et al., 207 
1993). The osmolarity of the intracellular solutions was 295 mOsM/L.  208 
To measure hKv1.1, hKv1.2, hKv1.3 and Shaker currents 15 or 200 ms long depolarization 209 
impulses were applied to +50 mV from a holding potential of -100 mV every 15 s. KCa3.1 210 
currents were elicited every 15 s with voltage ramps to +50 mV from a holding potential of 211 
-120 mV. For hKv11.1 channels, currents were evoked in every 30 s with a voltage step 212 
from a holding potential of -80 mV to +20 mV followed by a step to -40 mV, during the 213 
latter the peak current was measured. 214 
To acquire and analyze the measured data pClamp10 software package was used. Current 215 
traces were lowpass-filtered by the analog four-pole Bessel filters of the amplifiers. The 216 
sampling frequency was 2-50 kHz, at least twice the filter cut-off frequency. The effect of 217 
the toxins in a given concentration was determined as remaining current fraction (RF = I/I0, 218 
where I0 is the peak current in the absence of the toxin and I is the peak current at 219 
equilibrium block at a given toxin concentration). Points on the dose-response curves 220 
represent the mean of 3-8 independent measurements where the error bars represent the 221 
S.E.M. Data points were fitted with a two-parameter Hill equation, RF = IC50H/( 222 
IC50H+[Tx]H), where IC50 is the dissociation constant, H is the Hill coefficient and [Tx] is 223 
the toxin concentration. To estimate IC50 from three measured toxin concentrations in case 224 
of lower toxin affinity we used the Lineweaver-Burk analysis, where 1/RF was plotted as a 225 
function of toxin concentration, fitting a straight line to the points, where Kd = 1/slope. To 226 
estimate the IC50 using RF of a single toxin concentration H = 1 was used for the Hill 227 
equation. 228 
 229 
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3. RESULTS 230 
 231 
3.1 Chemical characterization 232 
 233 
For the first step of separation 220 mg of soluble venom protein were loaded in a Sephadex 234 
G-50 column, following the original technique (Ramirez et al., 1988). Three well-defined 235 
fractions were obtained (data not shown), which repeated exactly the same profile as earlier 236 
described. Fraction II was toxic (Ramirez et al., 1988) and used for the second 237 
chromatographic step. Fig.1A shows the CM-cellulose ion-exchange separation of this 238 
fraction. At least 14 fractions were recovered, from which numbers 10, 11 and 12 were 239 
additionally separated by HPLC as described in Material and Methods. Figures Fig. 1B to 240 
Fig.1D show the profile of separation of these fractions. For the sake of clarity and 241 
systematization of nomenclature the labeling of the components was based on the following 242 
rationale: roman number II for the Sephadex G-50 column, numbers 10, 11 and 12 for the 243 
sub-fractions obtained from CM-Cellulose column and the last number (third number 244 
separated by point) for the pure peptides. Fraction II-10 applied into the HPLC system 245 
separated at least 19 sub-fractions (Fig. 1B), which were analyzed by mass spectrometry. 246 
Only components further characterized were labeled in Fig.1B to 1D, among the many 247 
small peaks not well resolved in the figures due compression of the graphics. Sub-fractions 248 
II-10.4, II-10.5, II-10.9 and II-10.10 were all homogeneous peptides with molecular masses 249 
within the range expected for K+-channel specific toxins. For this reason the full amino acid 250 
sequence of these peptides were obtained, and their physiological effects on ion channels 251 
were assayed as described below. Similarly, fraction II-11 subjected to HPLC fractionation 252 
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resulted in at least 27 sub-fractions (Fig.1C). Fraction II-12 separated 15 components, as 253 
shown in Fig.1D. Peptides eluted as II-12.5 and II-12.8 were homogeneous and were 254 
completely sequenced and used for physiological assays. It is interesting to observe that 255 
among the various sub-fractions obtained from fraction II-11 (the most diverse fraction, 256 
showing many components) contained identical peptides that were eluted either in sub-257 
fraction II-10 or II-12. As expected there are cross-contaminations of these small basic 258 
peptides when separated by HPLC. Peptide eluted as number II-11.10 is identical to 259 
component II-10.5 and peptide II-11.11 is identical to component II-12.8. In summary, 260 
from fraction II-10 to II-12 six peptides were obtained in pure form, sequenced and assayed 261 
for pharmacological action. Many other components were identified by mass spectrometry 262 
analysis (Table 1S), but were not further studied, for three main reasons: i) the molecular 263 
weight correspond to peptides expected to modify normal Na+-channel functions, such as 264 
peptide II-10.16 in Fig.1B, peptides II-11.20, II-11.21 and II-11.22 in Fig.1C and peptides 265 
II-12.11, II-12.12 and II-12.13 in Fig.1D (see supplementary Table 1); ii) the molecular 266 
mass was under the expected values for a K+-channel toxin, such as peptide II-10.1, peptide 267 
II-10.2 in Fig.1B; peptides II-11.4 and II-11.5 in Fig.1C, and peptide II-12.2 in Fig.1D (see 268 
supplementary Table 1); iii) the quantity of material obtained was too low, not enough for 269 
fully chemical and functional analysis (labeled ND or NI in supplementary Table 1). The 270 
six purified and characterized peptides are in very small quantities in the venom, less than 271 
1%. The percentage yields of these peptides after purification as shown in Fig.1B were: 272 
peptide II-10.4 (0.2%), peptide II-10.5 (0.09%), peptide II-10.9 (0.05%), peptide II-10.10 273 
(0.04%), whereas for peptides II-12.5 and II-12.8 of Fig.1D were only 0.16% and 0.07%, 274 
respectively. The complete primary structures of peptides II-10.4, II-10.5, II-10.10 were 275 
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obtained directly by Edman degradation of native peptide, confirmed after reduction and 276 
alkylation, without need for cleavage, whereas peptides II-12.5 and II-12.8 were chemically 277 
treated with cyanogen bromide. Peptide II-10.9 was digested with protease V8, as described 278 
in Material and Methods. Fig.2 shows the amino acid sequences determined, as well as the 279 
molecular weights found: II-10.4 (3804.2 Da); II-10.5 (4124.0 Da); II-10.9 (4874.0 Da); II-280 
10.10 (3907.0 Da); II-12.5 (4339.9 Da) and II-12.8 (4211.9 Da).  281 
 282 
3.2 Electrophysiological characterization 283 
 284 
Among the K+ channels involved in the screening, the voltage-dependent K+-channel Kv1.2 285 
is the main target of the α-KTx peptides isolated from the C. tecomanus venom. Toxins II-286 
10.4 (elution time 24.12), II-10.5 (elution time 26.22), II-12.5 (elution time 23.84) and II-287 
12.8 (elution time 26.75) inhibited Kv1.2 currents reversibly (Fig.3 A-D) with IC50 values 288 
3.6 nM (H = 1.1), 0.3 nM (H = 1.1), 0.7 nM (H = 1.2) and 2.9 nM (H = 0.9) respectively 289 
(Fig.3 E). The insets to the Figs. 6A-D show, that the blocking effect of peptides II-12.5 290 
and II-12.8 were completely reversible during the time-scale of the wash-out period 291 
whereas very slow and incomplete relieve of the block is observed for peptides II-10.4 and 292 
II-10.5 upon washing the recording chamber with toxin-free solution.  The effect of these 293 
venom components on whole-cell Kv1.1, Kv1.3, Shaker-IR and KCa3.1 currents was also 294 
determined in order to characterize the selectivity of the peptides.  295 
Toxin II-10.4 slightly inhibited Kv1.3 currents (RF = 0.88) in 10 nM concentration whereas 296 
it was not effective on the other ion channels included in this study (data not shown). 297 
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Single-point estimation of the IC50 using RF=0.88 at 10 nM and assuming 1:1 298 
channel:toxin stoichiometry gives IC50 = 72 nM for the inhibition of Kv1.3.   299 
On the other hand, 10 nM toxin II-10.5 reversibly inhibited the whole-cell Kv1.3, Shaker 300 
and KCa3.1 (Fig.4 A-C) currents but not the Kv1.1 channels (data not shown). IC50 values 301 
were the following: 8.3 nM (H = 0.8) for Kv1.3, 22.0 nM for Shaker-IR and 6.7 nM (H = 302 
1.1) for KCa3.1 (Fig.4 D, E).  303 
The peptide eluting at 23.84 min (II-12.5) inhibited Kv1.3 reversibly with IC50 = 26.2 nM 304 
(Fig. 5.). It slightly blocked KCa3.1 (RF = 0.83) in 10 nM which results in an estimated 305 
IC50 = 56 nM using a single-point estimation of the IC50 (data not shown). Neither Kv1.1 306 
nor Shaker K+ channels were inhibited by peptide II-12.5 (data not shown)  307 
Toxin II-12.8 (eluting time 26.75) inhibited Kv1.1 reversibly with an IC50 = 4.8 nM (H = 308 
0.8) (Fig. 6.) whereas other channels included in this study (Kv1.3, Shaker and KCa3.1) 309 
were not affected by the peptide.  310 
The peptide eluting at 29.61 min (toxin II-10.9), which belongs to the γ-KTx family, 311 
inhibited the Kv11.1 (hERG) channel with IC50 = 16.9 nM, whereas this peptide did not 312 
block the closely related Kv10.1 channel at 10 nM concentration (Fig 7.). Toxin II-10.9 did 313 
not inhibit the other channels tested (Kv1.1, Kv1.2, Kv1.3, Shaker, KCa3.1) at 10 nM  314 
concentration (data not shown). 315 
The pharmacological data obtained for Kv1.1, Kv1.2, Kv1.3, Shaker and KCa3.1 are 316 
summarized in Fig. 8 where the remaining current fraction at equilibrium block is shown in 317 
the presence of 10 nM II-10.4, II-10.5, II-10.9, II-10.10, II-12.5 and II-12.8. As pointed out 318 
above analysis of the current inhibition at significantly higher peptide concentrations was 319 
unrealistic due to the limited amount of the peptides. Peptide II-10.10 was also assayed for 320 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
possible antimicrobial activity and was shown to be inactive using up 10 µM concentration 321 
(data not shown), 322 
 323 
 324 
 325 
4. DISCUSSION 326 
 327 
The source of the venoms reported in this paper was a scorpion species earlier known as a 328 
subspecies of Centruroides limpidus (Possani et al., 1980) but was recently renamed simply 329 
as Centruroides tecomanus, instead of Centruroides limpidus tecomanus (Valdez-330 
Velazquez et al., 2013). Earlier studies indicated that the venom of this scorpion is a rich 331 
source of peptides that interfere with the normal function of Na+-channels and the venom is 332 
very toxic to mammals (Martin et al., 1988; Ramirez et al., 1988). Actually, a recent 333 
publication regarding the proteomic and transcriptomic analysis of this venom reported the 334 
presence of 24 different amino acid sequences of peptides belonging to the Na+-channel 335 
specific toxin family (Valdez-Velazquez et al., 2013). In the same communication only four 336 
putative K+-channels blockers of the subfamily α-KTx were identified. The proteomic 337 
analysis reported the identity of peptide II-10.4 (molecular weight 3804 Da), peptide II-338 
10.5 (molecular weight 4124 Da) and peptide II-12.8 (molecular weight 4212 Da), as 339 
shown in Table 1 of Valdez-Velazquez et al (Valdez-Velazquez et al., 2013). The amino 340 
acid sequence of peptide II-10.4 determined here (Fig. 2) is identical to the expected 341 
sequence inferred from the transcriptomic analysis (see component Ct33, of Fig. 5 of the 342 
publication by (Valdez-Velasquez et al., 2013), except that an extra segment of six residues 343 
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was shown at the N-terminal segment, plus an additional Lysine at the C-terminal region of 344 
component Ct33 identified from the transcriptome, compared to II-10.4. These differences 345 
are assumed to be a postranslational modification of the peptide. Another almost identical 346 
peptide to Ct27 of Valdez-Velazquez et al. 2013 paper was toxin II-12.8. Here the toxin II-347 
12.8 shows an Alanine instead of Valine in position 25 found in Ct27. The extra Glycine in 348 
the transcriptome analysis of Ct27 means that very likely our toxin II-12-8 is amidated at 349 
the C-terminal residue, also due to posttranslational processing during maturation of the 350 
peptide.   These small differences are not contradictory and somehow were expected, since 351 
the transcriptomic analysis is not exhaustive and was conducted with venomous gland of 352 
only two scorpions (4 glands, each scorpion has a pair of glands), whereas the venom 353 
separation for this communication was obtained from several hundred individuals (220 mg, 354 
the first Sephadex column separation corresponds to the extraction of at least 100 355 
scorpions). Yet, the amount of the pure peptides obtained here are under 1% of the soluble 356 
venom used. Variations certainly occur among individual scorpions and also possibly to 357 
genre differences. The soluble venom used was obtained from male and female scorpions 358 
together. The systematic numbers assigned to these purified peptides were done according 359 
to previous information available in the UniProt Knowledgebase data. The corresponding 360 
systematic numbers are indicated in the section of Material and Methods.  361 
 362 
Guided by the primary amino acid sequences of the peptides we aimed to characterize their 363 
K+ channel blocking potencies, find similarities to other known peptides and compare their 364 
selectivity (Table 1). Due to the limited amount of the purified natural peptides we involved 365 
the following ion channels in this study: Three closely related voltage gated channels, 366 
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Kv1.1, which is expressed in chondrocytes, brain, heart and skeletal muscle (Beckh and 367 
Pongs, 1990; Gutman et al., 2005; Varga et al., 2011), Kv1.2, which is present in neurons, 368 
heart and smooth muscle (Bakondi et al., 2008; Gutman et al., 2005; Rusznak et al., 2008) 369 
and Kv1.3, which plays key role in the activation of lymphocytes (Chandy et al., 2004; 370 
Panyi et al., 2006); Kv10.1 (EAG), with oncogenic relevance (Pardo et al., 1999); Kv11.1 371 
(ERG) which pays key role in the cardiac action potential (Sanguinetti et al., 1995); 372 
KCa3.1, which is also present in lymphocytes (Chandy et al., 2004; Panyi et al., 2006); and 373 
the Drosophila Shaker, which is frequently used in structure-function studies (Panyi and 374 
Deutsch, 2006). Interestingly all four α-KTx peptides inhibited Kv1.2 in nanomolar 375 
concentration (Fig. 8). Peptide II-10.4 shows 97% sequence identity with cobatoxin 376 
(CoTx1), isolated from the venom of Centruroides noxius, which also inhibits Kv1.2 with 377 
IC50 = 27nM (Table 1). CoTx also inhibits Kv1.1 (IC50 = 24.4 µM), Kv1.3 (IC50 = 5.3 µM), 378 
Shaker (IC50 = 1 µM) and KCa3.1 (IC50 = 7.1 µM) channels, however these values are 379 
more than 100 fold higher than that of Kv1.2; therefore CoTx fulfills the criteria of 380 
selectivity to Kv1.2 (Giangiacomo et al., 2004). Toxin II-10.4 inhibited Kv1.3 with an 381 
estimated IC50 = 72 nM, however due to the limited amount of natural peptide we could not 382 
determine IC50 on Kv1.3 with higher accuracy nor taking measurements on the other 383 
channels in micromolar concentration to compare peptide II-10.4 with CoTx.  384 
Among the peptides described II-10.5 is the highest affinity inhibitor of Kv1.2 (IC50 = 0.3 385 
nM) however this peptide also blocked the Kv1.3, Shaker-IR and KCa3.1 channels in 386 
nanomolar concentration. Peptide II-10.5 has 92% sequence identity with Css20 (from the 387 
venom of Centruroides suffusus suffusus), which inhibits Kv1.2 (IC50 = 1.26 nM) and 388 
Kv1.3 (IC50 = 7.21 nM) channels but has no effect on Kv1.1, Shaker-IR, KCa3.1 or Kv11.1 389 
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channels in 10 nM (Corzo et al., 2008). Toxin II-10.5 is also highly similar to Ce3 (89%) 390 
(Centruroides elegans) and CIITx1 (81%) (Centruroides limpidus). Ce3 was shown to 391 
inhibit Kv1.3 (IC50 = 366 nM) but was not effective on Shaker-IR and KCa3.1 channels in 392 
10 nM (Olamendi-Portugal et al., 2005) whereas CIITx1 was not tested specifically on any 393 
of the channels involved in this study; thus its selectivity profile is still unknown (Martin et 394 
al., 1994). 395 
Toxin II-12.5 inhibits Kv1.2, Kv1.3 and KCa3.1 channels in nanomolar concentrations. The 396 
amino acid sequence of II-12.5 is 97% identical to Ce2, 95% to Ce1 and 87% to Ce4 (all 397 
three isolated from Centruroides elegans). Ce2, Ce1 and Ce4 all inhibit Kv1.3 with half-398 
inhibiting concentrations of 0.25 nM, 0.71 nM and 0.98 nM, respectively and neither of 399 
them inhibited Shaker-IR nor KCa3.1 in 10 nM, however the effect of the peptides on 400 
Kv1.1 and Kv1.2 is unknown (Olamendi-Portugal et al., 2005). Margatoxin (MgTx, from 401 
Centruroides margaritatus) (Garcia-Calvo et al., 1993), which was shown to inhibit Kv1.1 402 
Kv1.2 and Kv1.3 channels with IC50 values 4.7 nM, 6.4 pM and 11.7 pM, respectively but  403 
does not inhibit Shaker-IR, Kv11.1 and KCa3.1 in 1nM  concentration (Bartok et al., 2014), 404 
shows 81% identity to II-12.5. 405 
Component II-12.8 has a sequence similar to Ce5 (92%), Ce4 (90%), Ce2 (89%), Ce1 406 
(86%) and MgTx (81%). Interestingly, the essential dyad of II-12.8 contains a serine in 407 
addition to the conserved lysine (Dauplais et al., 1997). This type of dyad is also present in 408 
Ce5. Peptide II-12.8 inhibits Kv1.1 and Kv1.2 but not Kv1.3, whereas Ce5 is effective on 409 
Kv1.3 (IC50 = 69 nM); unfortunately Ce5 was not tested on Kv1.1 and Kv1.2 (Olamendi-410 
Portugal et al., 2005). 411 
 412 
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The analysis of the sequence of II-10.9 shows 90% sequence similarity to CnErg1, which is 413 
a potent inhibitor of Kv11.1 (IC50 =8.5 nM) (Torres et al., 2003). So far the amino acid 414 
sequence of 29 γ-KTx peptides have been published, but only 5 of them were proved to 415 
inhibit Kv11.1, the others were classified to be in this family solely based on the primary 416 
amino acid sequence. Here we report a novel peptide, belonging to the group of γ-KTx, 417 
which shows several thousand-fold selectivity for Kv11.1 over the closely related Kv10.1 418 
and the other channels included in this study (Kv1.1, Kv1.2, Kv1.3, Shaker, KCa3.1).  419 
Although II-10.10 has a cysteine pattern similar to that of many α-KTx peptides (e.g. 420 
CoTx1, Fig. 9), the essential dyad, a characteristic pattern required for the interaction with 421 
K+ channels (Dauplais et al., 1997) cannot be identified. Although a positively charged 422 
amino acid (R) is present in II-10-10 in an equivalent position to K21 of CoTx1 the amino 423 
acid, which corresponds to Y30 in CoTx1, the part of the dyad which is usually 424 
hydrophobic and frequently aromatic in K+ channel blocker peptides cannot be identified in 425 
II-10.10. Since peptide II-10.10 did not inhibit any of the tested ion channels in 10 nM 426 
concentration (Fig. 8), and its primary amino acid sequence shows no significant similarity 427 
to any of the sequences in protein databases (pdb, swissprot, etc.) its function remains 428 
unknown. In addition this peptide was also assayed for possible antimicrobial activity with 429 
negative results. 430 
Overall, when compared to the 133 known α-KTx peptides (reviewed in (Bartok et al., 431 
2015)), the novel α-KTx peptides isolated from Centruroides tecomanus, described in this 432 
article show the highest sequence identities to peptides isolated from other species of the 433 
Centruroides genus. Most of the peptides mentioned above can inhibit multiple ion 434 
channels, however, the detailed selectivity profile for many of the peptides is yet to be 435 
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determined. Since all four α-KTx peptides of C. tecomanus inhibit Kv1.2 with high affinity 436 
but their additional target ion channels are different, and due to the high sequence identity 437 
of peptides II-10.5, II-12.5 and II-12.8, further studies involving docking simulations, the 438 
mutagenesis and synthesis of these peptides may provide valuable information of the 439 
molecular and structural determinants of the ion channel selectivity of K+ channel blocking 440 
scorpion toxins. 441 
 442 
5. CONCLUSIONS    443 
 444 
    The venom from the Mexican scorpion C. tecomanus contains four  different peptides 445 
composed of 32-39 amino acid residues, cross-linked by three disulfide bonds, that impair 446 
normal function of Kv1.2, Kv1.1, Kv1.3, Shaker and KCa3.1 ion-channels, at nanomolar 447 
concentrations. They belong to the known α-KTx family of scorpion peptides. Another 448 
peptide with 42 amino acid residues, cross-linked by four disulfide bonds, belonging to the 449 
γ-KTx family, block ERG-channel. A sixth new peptide with 32 amino acid residues, three 450 
disulfide bonds, is a peptide of unknown function, which does not affect the K+-channels 451 
assayed in this report. The pharmacological properties of the peptides described here will 452 
certainly be valuable tools for studies aimed at understanding the structure-function 453 
relationship of K+ channels.   454 
 455 
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 603 
FIGURE LEGENDS 604 
Figure 1: Venom fractionation and purification of peptides 605 
A. CM-Cellulose ion-exchange separation. The fraction II from Sephadex G-50 gel 606 
filtration (Ramírez et al., 1988) of C. tecomanus venom (132 mg) was applied to a column 607 
(0.9 x 30 cm) equilibrated with 20 mM ammonium acetate buffer, pH 4.7. The material was 608 
eluted with a linear salt gradient from 0 to 0.5 M NaCl run in the same buffer. At the end of 609 
the run a 1.0 M NaCl solution was applied to the column. Final recovery was about 80%. 610 
B. HPLC separation of fraction II-10. Fraction II-10 (190 µg) was applied to a C18 611 
reverse-phase analytical column and separated with a linear gradient from solution A (water 612 
in 0.12% TFA) to 60% solution B (acetonitrile in 0.10% TFA) run for 60 min. Note that 613 
only the peak components further analyzed are indicates, among many others, which are 614 
not evident due to compression of the figures. 615 
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C. HPLC separation of Fraction II-11. Fraction II-10 (130 µg) was applied to a C18 616 
reverse-phase analytical column and separated with a linear gradient from solution A (water 617 
in 0.12% TFA) to 60% solution B (acetonitrile in 0.10% TFA) run for 60 min. 618 
D. HPLC separation of Fraction II-12. Fraction II-10 (380 µg) was applied to a C18 619 
reverse-phase analytical column and separated with a linear gradient from solution A (water 620 
in 0.12% TFA) to 60% solution B (acetonitrile in 0.10% TFA) run for 60 min. 621 
 622 
Figure 2: Sequence of the new peptides from the venom of C. tecomanus  623 
First column shows the systematic number of the six peptides. Numbers on top of the 624 
sequences correspond to the position in the primary structure. Direct Sequence indicate the 625 
segment of the primary structure directly obtained from the sequencer and CnBr and V8 626 
digestion indicate the segment of peptides, whose primary structure determination required 627 
cleavage and separation by HPLC as indicated in Material and Methods. Last column 628 
indicates the elution time on the HPLC columns for each one of the peptides sequenced. 629 
 630 
Figure 3: Novel α-KTx peptides inhibit human Kv1.2 channels 631 
A-D, Inhibition of the hKv1.2 current. Currents were recorded in outside-out patch 632 
configuration in tsA201 cells transiently transfected with the gene encoding the hKv1.2 633 
channel. The patches were depolarized to +50 mV from a holding potential of -100 mV 634 
every 15 s. The traces show the K+ current before the application of the toxin (control) and 635 
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after reaching equilibrium block in the presence of 10 nM II-10.4 (A), II-10.5 (B), II-12.5 636 
(C) and II-12.8. Insets: Peak K+ currents were determined and plotted as a function of time.  637 
Grey bars mark the presence of the corresponding toxin in the extracellular solution.  638 
E, Concentration-dependence of the current block.  The remaining fraction of the Kv1.2 639 
current was calculated as I/I0, where I0 and I are the peak K+ currents measured in the 640 
control solution and upon reaching equilibrium block during bath perfusion with the test 641 
solution containing peptide II-10.4 (filled diamond), II-10.5 (filled circle), II-12.5 (filled 642 
triangle) and II-12.8 (filled square) at indicated concentrations. The voltage protocol and 643 
other experimental conditions were the same as in A-D. The superimposed solid lines are 644 
the Hill equations fitted to the data points (see Material and Methods). The best fit yielded 645 
IC50 values of 3.6 nM (H = 1.1) for II-10.4, 0.3 nM (H = 1.1) for II-10.5, 0.7 nM (H = 1.2) 646 
for II-12.5 and 2.9 nM (H = 0.9) for II-12.8. 647 
 648 
Figure 4: Effect of peptide II-10.5 on Kv1.3, Shaker-IR and KCa3.1 channels  649 
A-C, Currents were recorded in whole cell configuration in activate human lymphocytes 650 
(A) or outside-out patch configuration in tsA201 cells transiently transfected with the gene 651 
encoding the indicated channel (B, C). The traces show the K+ current before the 652 
application of the toxin (control) and after reaching equilibrium block in the presence of 10 653 
nM II-10.5. Insets: Peak K+ currents were determined and plotted as a function of time.  654 
Grey bars mark the presence of 10 nM II-10.5 in the extracellular solution.   655 
 656 
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Figure 5: Effect of peptide II-12.5 on the Kv1.3 channel 657 
A, Currents were measured in whole cell configuration in activated human lymphocytes. 658 
The traces show the K+ current before the application of the toxin (control) and after 659 
reaching equilibrium block in the presence of 10 nM II-12.5. Inset: Peak K+ currents were 660 
determined and plotted as a function of time. Grey bar marks the presence of 10 nM II-12.5 661 
in the extracellular solution.  B, The remaining fraction of the current was calculated as 662 
described in Fig.6 and the Materials and Methods. IC50 on was determined by the 663 
Lineweaver-Burk method resulted in IC50 = 26.2 nM. 664 
 665 
Figure 6: Effect of peptide II-12.8 on the Kv1.1 channel 666 
A, Currents were recorded in outside-out patch configuration in tsA201 cells transiently 667 
transfected with the gene encoding the hKv1.1 channel. The patches were depolarized to 668 
+50 mV from a holding potential of -100 mV every 15 s. The traces show the K+ current 669 
before the application of the toxin (control) and after reaching equilibrium block in the 670 
presence of 10 nM II-12.8. Inset: Peak K+ currents were determined and plotted as a 671 
function of time.  Grey bar marks the presence of the 10 nM toxin in the extracellular 672 
solution. B, The remaining fraction of the current was calculated as described in Fig.3 and 673 
the Materials and Methods. The superimposed solid line is the Hill equation fitted to the 674 
data points (see Material and Methods). The best fit yielded IC50 value of 4.8 nM (H = 0.8). 675 
 676 
Figure 7: Effect of II-10.9 on Kv11.1 (hERG) and Kv10.1 (EAG). 677 
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A, C, Currents were recorded in whole cell (A) or outside-out patch (C) configuration in 678 
tsA201 cells transiently transfected with the gene encoding the indicated channel. Currents 679 
were evoked wit voltage protocols described in Material and Methods. The traces show the 680 
K+ current before the application of the toxin (control) and after reaching equilibrium block 681 
in the presence of 10 nM II-10.9. Insets: Peak K+ currents were determined and plotted as a 682 
function of time.  Grey bars mark the presence of toxin II-10.9 in 10 nM concentration in 683 
the extracellular solution. B, The remaining fraction of the current was calculated as 684 
described in Fig.3 and the Materials and Methods. IC50 on was determined by the 685 
Lineweaver-Burk method resulted in IC50 = 16.9 nM 686 
 687 
Figure 8: Comparison of the selectivity of the C. tecomanus toxins.  688 
Effect of the peptides were measured in 10 nM concentration on Kv1.1, Kv1.2, Kv1.3, 689 
Shaker and KCa3.1 channels as described previously. The remaining fraction of the current 690 
was calculated as described in Fig.3 and the Materials and Methods. 691 
 692 
Figure 9: Characteristic patterns in the C. tecomanus peptides 693 
A, The primary amino acid sequences of II-10.10 and CoTx1 were aligned by pairing their 694 
cysteine residues (shown in boxes). The position of the two amino acids required for K+-695 
channel inhibition in CoTx are labeled as dyad. B, The primary amino acid sequences of II-696 
10.5, II-12.5 and II-12.8 were aligned by matching their cysteine residues. Different 697 
residues in the equivalent positions are shown in bold letters. 698 
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 699 
Table 1: Blast analysis of the novel C. tecomanus toxins 700 
Sections in the table contain the name, accession number and sequence of peptides with 701 
high sequence identity to II-10.4 (A), II-10.5 (B), II-12.5 (C), II-12.8 (D) and II-10.9 (E), 702 
and their IC50 values measured on the listed channels. Missing values represent that effect 703 
on a given channel is not determined (ND) or the peptide does not block the channel (-). 704 
 705 
Supplementary Table 1: Mass spectrometry determination of peptides 706 
MW, indicates the molecular weight experimentally determined; ND, means not 707 
determined; NI means not identified 708 
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toxin name accession sequence identity Kv1.1 Kv1.2 Kv1.3 Shaker-IR KCa3.1 
A 
II-10.4   AVCVYRTCDKDCKRRGYRSGKCINNACKCYPYA
 
  - 3.6 nM ~72 nM - - 
CoTx1 O46028.1 AVCVYRTCDKDCKRRGYRSGKCINNACKCYPYG
 
97% 24.4 µM 27 nM 5.3 µM 1 µM 7.5 µM 
  
B 
II-10.5   IFINVKCSSPQQCLKPCKKAFGQHAGGKCINGKCKCYP   - 0.3 nM 8.3 nM 12.4 nM 6.4 nM 
Ce3 P0C163.1 IFINVKCSLPQQCLRPCKDRFGQHAGGKCINGKCKCYP
 
89% ND ND 366 nM - - 
CllTx1 P45629.1 ITINVKCTSPQQCLRPCKDRFGQHAGGKCINGKCKCYP 87% ND ND ND ND ND  
Css20 P85529.1 IFINVKCSSPQQCLKPCKAAFGISAGGKCINGKCKCYP 92% - 1.3 nM 7.2 nM - - 
C 
II-12.5        TIINVKCTSPKQCLKPCKDLYGPHAGEKCMNGKCKCYKI   - 0.7 nM 26.2 nM - ~56 nM 
Ce2 P0C162.1 TIINVKCTSPKQCLKPCKDLYGPHAGAKCMNGKCKCY 97% ND ND 0.25 nM - - 
Ce1 P0C161.1 TVINVKCTSPKQCLKPCKDLYGPHAGAKCMNGKCKCY 95% ND ND 0.71 nM - - 
Ce4 P0C164.1 TIINVKCTSPKQCLLPCKEIYGIHAGAKCMNGKCKCYKI 87% ND ND 0.98 nM - - 
MgTx P40755.1 TIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGKCKCYP 81% 4.7 nM 6.4 pM 11.7 pM - - 
D 
II-12.8   TIINVKCTSPKQCLLPCKQIYGPHAGAKCMNGKCHCSKI   4.8 nM 2.9 nM - - - 
Ce5 P0C165.1 TIINVKCTSPKQCLPPCKEIYGRHAGAKCMNGKCHCSKI 92% ND ND 69 nM - - 
Ce4 P0C164.1 TIINVKCTSPKQCLLPCKEIYGIHAGAKCMNGKCKCYKI 90% ND ND 0.98 nM - - 
Ce2 P0C162.1 TIINVKCTSPKQCLKPCKDLYGPHAGAKCMNGKCKCY 89% ND ND 0.25 nM - - 
Ce1 P0C161.1 TVINVKCTSPKQCLKPCKDLYGPHAGAKCMNGKCKCY 86% ND ND 0.71 nM - - 
MgTx P40755.1 TIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGKCKCYP 81% 4.7nM 6.4pM 11.7 pM - - 
E hERG 
II-10.9   DRDSCIDKSRCSKYGYYQECQDCCKKAGHNRGTCMFFKCKCA 16.9 nM 
    CnErg1 Q86QT3.1 DRDSCVDKSRCAKYGYYQECQDCCKNAGHNGGTCMFFKCKCA 90% 8.8 nM 
    CeErgTx5 P0C893.1 DRDSCIDKSRCSKYGYYQECQDCCKKAGHNGGTCMFFKCKCA 98% ND 
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    Peptides         1                                10       Sequence           20                                 30        33                         Molecular Weight  
                              ǀ                                   ǀ                                        ǀ                                      ǀ            ǀ                                         (Da) 
  II-10.4    AVCVYRTCDKDCKRRGYRSGKCINNACKCYPYA                         3804.2 
                   :-----direct sequence------------------------------ 
                            1                            10                                     20                                    30                          38  
                   ǀ                               ǀ                                         ǀ                                        ǀ                              ǀ                                                                        
 II-10.5     IFINVKCSSPQQCLKPCKKAFGQHAGGKCINGKCKCYP               4124.0 
                   :-----direct sequence------------------------------------- 
                            1                              10                                    20                                    30                                    40     42  
                            ǀ                                 ǀ                                        ǀ                                        ǀ                                         ǀ        ǀ                                                                         
 II-10.9    DRDSCIDKSRCSKYGYYQECQDCCKKAGHNRGTCMFFKCKCA  4874.0 
                   :-----direct sequence-------- :----V8 digestion--------------- 
                              1                                10                                     20                                30   32  
                    ǀ                                   ǀ                                        ǀ                                    ǀ       ǀ                                                                        
 II-10.10   IRRYCDPRVCDRECLEKGKYFGRCIRDICKCN                                3907.0 
                    :-----direct sequence-------------------------- 
                              1                            10                                    20                                    30                               39  
                    ǀ                               ǀ                                        ǀ                                        ǀ                                   ǀ                                                                        
 II-12.5     TIINVKCTSPKQCLKPCKDLYGPHAGEKCMNGKCKCYKI             4339.9 
                    :-----direct sequence------------------------ :--CnBr----  
                              1                           10                                   20                                   30                                39  
                    ǀ                               ǀ                                      ǀ                                        ǀ                                    ǀ                                                                        
 II-12.8     TIINVKCTSPKQCLLPCKQIYGPHAGAKCMNGKCHCSKI               4211.9 
                    :-----direct sequence------------------------ :--CnBr--- 
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II-10.10 IRRYCDPRYCDRECLEKGKYFGRCIRDICKCN
CoTx1 AVCVYRTCDKDCKRRGYRSGKCINNACKCYPYG
dyad
II-10.5 IFINVKCSSPQQCLKPCKKAFGQHAGGKCINGKCKCYP
II-12.5     TIINVKCTSPKQCLKPCKDLYGPHAGEKCMNGKCKCYKI
II-12.8 TIINVKCTSPKQCLLPCKQIYGPHAGAKCMNGKCHCSKI
A
B
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Highlights 
1. Four new peptides of the α-KTx family of scorpion venom components are described. 
2. A novel blocking peptide that blocks regular function of ERG-channels is reported. 
3. A 32 amino acid long peptide with no apparent pharmacological action on K
+
-channels was 
found. 
4. For the first time it is demonstrated that venom from C. tecomanus also has peptides that block 
ion-channel function. 
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